{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:03:35Z","timestamp":1769972615436,"version":"3.49.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9,12]]},"DOI":"10.1097\/qad.0b013e32830163ad","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T07:08:33Z","timestamp":1219820913000},"page":"1709-1717","source":"Crossref","is-referenced-by-count":41,"title":["Clinical impact of patient population differences and genomic variation in efavirenz therapy"],"prefix":"10.1097","volume":"22","author":[{"given":"Jennifer","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A","family":"Aberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-5-20210130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1258\/095646205774988109","article-title":"Causes of the decline in AIDS deaths, United States, 1995\u20132002: prevention, treatment or both?","volume":"16","author":"Holtgrave","year":"2005","journal-title":"Int J STD AIDS"},{"key":"R3-5-20210130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R4-5-20210130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.aids.0000196178.73174.24","article-title":"Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers","volume":"20","author":"Sabin","year":"2006","journal-title":"AIDS"},{"key":"R7-5-20210130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R8-5-20210130","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"R9-5-20210130","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/00002030-200109070-00011","article-title":"Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz","volume":"15","author":"Lucas","year":"2001","journal-title":"AIDS"},{"key":"R10-5-20210130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1310\/M47B-R51C-X0MC-K3GW","article-title":"Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study","volume":"3","author":"Keiser","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R11-5-20210130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00126334-200404010-00003","article-title":"Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study)","volume":"35","author":"Pulido","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-5-20210130","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-5-20210130","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/01.qai.0000243092.40490.26","article-title":"Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir\/ritonavir, or stavudine","volume":"43","author":"Bartlett","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-5-20210130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00003088-200140120-00002","article-title":"Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors","volume":"40","author":"Smith","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R17-5-20210130","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2174\/1381612043384835","article-title":"Anti-HIV drug distribution to the central nervous system","volume":"10","author":"Thomas","year":"2004","journal-title":"Curr Pharm Des"},{"key":"R18-5-20210130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00023210-200216090-00002","article-title":"Clinical implications of CNS penetration of antiretroviral drugs","volume":"16","author":"Wynn","year":"2002","journal-title":"CNS Drugs"},{"key":"R19-5-20210130","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/00002030-200110190-00022","article-title":"Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men","volume":"15","author":"Taylor","year":"2001","journal-title":"AIDS"},{"key":"R20-5-20210130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00002018-200629100-00004","article-title":"Neuropsychiatric complications of antiretroviral therapy","volume":"29","author":"Cespedes","year":"2006","journal-title":"Drug Saf"},{"key":"R22-5-20210130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"R23-5-20210130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R24-5-20210130","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group Study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R25-5-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R26-5-20210130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"R28-5-20210130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","article-title":"Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence","volume":"38","author":"Fumaz","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-5-20210130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00002030-200202150-00009","article-title":"Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort","volume":"16","author":"Hirschel","year":"2002","journal-title":"AIDS"},{"key":"R30-5-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","article-title":"Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients","volume":"3","author":"Perez-Molina","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R31-5-20210130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1310\/P7MJ-K2WD-T1FY-AU8L","article-title":"Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse","volume":"4","author":"Juethner","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R32-5-20210130","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1080\/09540120500038371","article-title":"Recreational substance use and tolerance of efavirenz in HIV-1 infected patients","volume":"17","author":"Faggian","year":"2005","journal-title":"AIDS Care"},{"key":"R33-5-20210130","first-page":"9C","article-title":"Management of depression and related neuropyschiatric symptoms associated with HIV\/AIDS and antiretroviral therapy","volume":"12","author":"Halman","year":"2001","journal-title":"Can J Infect Dis"},{"key":"R34-5-20210130","first-page":"L40","article-title":"Impact of race on nervous system side-effects of subjects taking efavirenz","volume":"9","author":"Seekins","year":"2004","journal-title":"Antivir Ther"},{"key":"R37-5-20210130","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/01.aids.0000237369.41617.0f","article-title":"Effectiveness of highly-active antiretroviral therapy by race\/ethnicity","volume":"20","author":"Silverberg","year":"2006","journal-title":"AIDS"},{"key":"R38-5-20210130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5414\/CPP40507","article-title":"Population pharmacokinetic meta-analysis with efavirenz","volume":"40","author":"Barrett","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R39-5-20210130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1067\/mcp.2003.22","article-title":"Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection","volume":"73","author":"Csajka","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R40-5-20210130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007691-200406000-00008","article-title":"Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects","volume":"26","author":"Stahle","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R41-5-20210130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.47.1.130-137.2003","article-title":"Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: an Adult AIDS Clinical Trial Group Study 398","volume":"47","author":"Pfister","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-5-20210130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R43-5-20210130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV nonnucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R44-5-20210130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R45-5-20210130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R46-5-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R47-5-20210130","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Rodriguez-Novoa","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R48-5-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R49-5-20210130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz","volume":"15","author":"Klein","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R50-5-20210130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles","volume":"311","author":"Lang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R51-5-20210130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R52-5-20210130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R53-5-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R54-5-20210130","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R55-5-20210130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/499364","article-title":"Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study","volume":"42","author":"Ribaudo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R56-5-20210130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R57-5-20210130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"R58-5-20210130","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1023\/A:1016430825740","article-title":"Differential modulation of P-glycoprotein expression and activity by nonnucleoside HIV-1 reverse transcriptase inhibitors in cell culture","volume":"19","author":"Stormer","year":"2002","journal-title":"Pharm Res"},{"key":"R61-5-20210130","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and\/or Nelfinavir: an Adult AIDS Clinical Trials Group Study","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"R62-5-20210130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.fpc.0000230413.97596.fa","article-title":"Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group Study","volume":"16","author":"Motsinger","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R63-5-20210130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":"Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"R65-5-20210130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/ng1454","article-title":"Changing the paradigm from \u2018race\u2019 to human genome variation","volume":"36","author":"Royal","year":"2004","journal-title":"Nat Genet"},{"key":"R66-5-20210130","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/ng1435","article-title":"Genetic variation, classification and \u2018race\u2019","volume":"36","author":"Jorde","year":"2004","journal-title":"Nat Genet"},{"key":"R67-5-20210130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/01.HYP.0000118019.28487.9c","article-title":"Overlap between whites and blacks in response to antihypertensive drugs","volume":"43","author":"Sehgal","year":"2004","journal-title":"Hypertension"},{"key":"R68-5-20210130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s004390050928","article-title":"Estimating European admixture in African Americans by using microsatellites and a microsatellite haplotype (CD4\/Alu)","volume":"104","author":"Destro-Bisol","year":"1999","journal-title":"Hum Genet"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-200809120-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:50:28Z","timestamp":1738345828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200809120-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,12]]},"references-count":56,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32830163ad","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9,12]]}}}